» Articles » PMID: 16738536

Changes in Serum Calcium, Phosphate, and PTH and the Risk of Death in Incident Dialysis Patients: a Longitudinal Study

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2006 Jun 2
PMID 16738536
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated bone mineral parameters have been associated with mortality in dialysis patients. There are conflicting data about calcium, parathyroid hormone (PTH), and mortality and few data about changes in bone mineral parameters over time. We conducted a prospective cohort study of 1007 incident hemodialysis and peritoneal dialysis patients. We examined longitudinal changes in bone mineral parameters and whether their associations with mortality were independent of time on dialysis, inflammation, and comorbidity. Serum calcium, phosphate, and calcium-phosphate product (CaP) increased in these patients between baseline and 6 months (P<0.001) and then remained stable. Serum PTH decreased over the first year (P<0.001). In Cox proportional hazards models adjusting for inflammation, comorbidity, and other confounders, the highest quartile of phosphate was associated with a hazard ratio (HR) of 1.57 (1.07-2.30) using both baseline and time-dependent values. The highest quartiles of calcium, CaP, and PTH were associated with mortality in time-dependent models but not in those using baseline values. The lowest quartile of PTH was associated with an HR of 0.65 (0.44-0.98) in the time-dependent model with 6-month lag analysis. We conclude that high levels of phosphate both at baseline and over follow-up are associated with mortality in incident dialysis patients. High levels of calcium, CaP, and PTH are associated with mortality immediately preceding an event. Promising new interventions need to be rigorously tested in clinical trials for their ability to achieve normalization of bone mineral parameters and reduce deaths of dialysis patients.

Citing Articles

Association between serum intact parathyroid hormone and survival in dialysis patients.

Luo C, Bian X, Ji C, Wang H, Ma J, Zhong C Int Urol Nephrol. 2024; 57(3):1019-1028.

PMID: 39557805 DOI: 10.1007/s11255-024-04288-y.


Crosstalk between kidney and bone: insights from CKD-MBD.

Suzuki K, Soeda K, Komaba H J Bone Miner Metab. 2024; 42(4):463-469.

PMID: 39060498 DOI: 10.1007/s00774-024-01528-0.


The association between circulating 25-hydroxyvitamin D and pancreatic cancer: a systematic review and meta-analysis of observational studies.

Shen Y, Xia J, Yi C, Li T, Wang P, Dai L Eur J Nutr. 2024; 63(3):653-672.

PMID: 38170272 DOI: 10.1007/s00394-023-03302-w.


Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.

Nakayama M, Kobayashi S, Kusakabe M, Ohara M, Nakanishi K, Akizawa T Clin Exp Nephrol. 2023; 28(2):153-164.

PMID: 37910313 PMC: 10808471. DOI: 10.1007/s10157-023-02406-1.


Anemia biomarkers and mortality in hemodialysis patients with or without diabetes: A 10-year follow-up study.

Asmar J, Chelala D, El Hajj Chehade R, Azar H, Finianos S, Aoun M PLoS One. 2023; 18(1):e0280871.

PMID: 36719878 PMC: 9888689. DOI: 10.1371/journal.pone.0280871.